H.C. Wainwright lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $74 from $76 and keeps a Buy rating on the shares following the Q3 report. The firm expects mirdametinib FDA approval in NF1-associated plexiform neurofibromas in Q1 of 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks Therapeutics reports Q3 EPS (72c), consensus (75c)
- SpringWorks Therapeutics announces data on mirdametinib
- SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study
- SWTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- SpringWorks Therapeutics’ ogsiveo shows long-term efficacy in Phase 3 trial